Get started
Author

Tom G. Punnen

Observed names: Tom G. Punnen, Tom G Punnen, Tom Punnen
ORCID: 0009-0000-2969-2360
Observed ORCID: 0009-0000-2969-2360
OpenAlex ID: A5114742498
Faster and better than a physician?: Assessing diagnostic proficiency of ChatGPT in misdiagnosed individuals with neuromyelitis optica spectrum disorder
2024 · Kevin Shan, Mahi A. Patel, et al. · Journal of the Neurological Sciences · 5
Clinical and radiological implications of subpotent generic fingolimod in multiple sclerosis: a case series
2024 · Darin T. Okuda, Lauren M. Tardo, et al. · Therapeutic Advances in Neurological Disorders · 5
Understanding the Therapeutic Impact of Disease-Modifying Therapies or No Treatment on Enlarging T1-Weighted Hypointense Lesions and Total T1-Weighted Hypointense Lesion Volume in MS
2026 · Darin T. Okuda, Tom G. Punnen, et al. · American Journal of Neuroradiology · 1
Clinical and radiological outcomes of directed treatment transitions from Gilenya ® to generic fingolimod
2026 · Mahi A Patel, Tom G Punnen, et al. · Multiple Sclerosis Journal · 1
Selective Radiological Vulnerability and Neuropsychiatric Challenges in Anti-DPPX Antibody-Associated Encephalitis (P10-8.003)
2025 · Tom Punnen, Darin Okuda · Neurology · 1
Cardiometabolic disease is associated with distinct proteomic signatures of acute disease activity in multiple sclerosis
2026 · Darin T. Okuda, Katy W. Burgess, et al. · Neurotherapeutics
Corrigendum to “Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis” [Clin. Immunol. 288 (2026) 110766]
2026 · Darin T. Okuda, Benjamin J. Anderson, et al. · Clinical Immunology
PDF
Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis
2026 · Darin T. Okuda, Benjamin J. Anderson, et al. · Clinical Immunology
Clinical and Radiological Outcomes in People with Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Following Ravulizumab Treatment (AMAZE) (P4-1.009)
2026 · Darin Okuda, Katy Burgess, et al. · Neurology
Selective Multi-Analyte Serum Protein Differences Between Gilenya and Generic Fingolimod in Multiple Sclerosis
2026 · Darin T. Okuda, Isabella J. Huddleston, et al. · SSRN Electronic Journal
Why the disease modifying therapy transition? Investigating the reasons and clinical consequences in multiple sclerosis
2025 · Darin T. Okuda, Tom G. Punnen, et al. · Multiple Sclerosis and Related Disorders
Patient Participation in AI for Health Curriculum
2025 · Kirsten Ostherr, Waverly Huang, et al. · Journal of Participatory Medicine
Clinical and Radiological Outcomes in People with Aquaporin-4 IgG Positive Neuromyelitis Optica Spectrum Disorder Following Ravulizumab Treatment (AMAZE) (P7-8.018)
2025 · Darin Okuda, Mahi Patel, et al. · Neurology
Diagnostic accuracy and bias in open access and subscription-based large language models for multiple sclerosis and neuromyelitis optica spectrum disorder
2025 · Tom G. Punnen, Kevin S. Shan, et al. · Intelligence-Based Medicine
Works count: 14
Citation count: 13
H-index: 2
I10-index:
Year
Topic
Type